GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Debt-to-Revenue

Thor Medical ASA (LTS:0R6Y) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Thor Medical ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Thor Medical ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Thor Medical ASA's annualized Revenue for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Thor Medical ASA Debt-to-Revenue Historical Data

The historical data trend for Thor Medical ASA's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Debt-to-Revenue Chart

Thor Medical ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Thor Medical ASA Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Thor Medical ASA's Debt-to-Revenue

For the Biotechnology subindustry, Thor Medical ASA's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's Debt-to-Revenue falls into.



Thor Medical ASA Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Thor Medical ASA's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Thor Medical ASA's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Thor Medical ASA Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA (LTS:0R6Y) Business Description

Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (LTS:0R6Y) Headlines

No Headlines